GNPX Company Profile and Key Details

GNPX has shown mixed momentum, gaining 14.29% over the past week and -80.23% over the past quarter, though year-to-date performance is up 14.29%. Short-term trend indicators are bullishly aligned (SMA20 4.51%, SMA50 -31.54%, SMA200 -78.8%). The stock’s 14-day RSI is 42.66 (neutral), while the ATR of 0.38 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -96.0% below its high and over 28.65% above its low. Average 10-day trading volume of 914.54 thousand shares is slightly above the 3-month average of 820.90 thousand, indicating heightened recent market interest.

Genprex, Inc. has 33.47 million shares outstanding. The public float is 33.36 million shares, elevated short interest at 4.11% of float. This equals 1.37 million shares. The short ratio is 1.24 days. Institutional investors hold 2.24% of the float. Insiders own 0.33%. ROTH JACK A holds 1.34 million shares, VACZY CATHERINE M has 265.00 thousand shares and Nance Christy M. has 50.00 thousand shares.

Genprex, Inc. generated EPS of -$47.66 over the past year. Five-year average earnings growth is 27.47%. The latest quarter delivered EPS of -$5.00. The next quarter is forecast at $nan. Next year's EPS is expected at $39.47. Genprex, Inc. earnings surprise history is a mixed track record. The quarter that ended November 14, 2025, missed forecasts by -60.0%. The prior quarter beat by -59.52%. Over the last six quarters, Apple has recorded several small beats. These include 30.43% in August 09, 2024.

Genprex, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $19.99. This means the shares are trading below this model’s fair value.

Genprex, Inc. (NASDAQ:GNPX) closed at $2.20 USD, gaining $0.20 (10.00%) from the previous close of $2.00. The stock is currently mid-range between its 52-week high and low $1.71 and $55.00. With a market capitalization of about $3.59 million, Genprex, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.80). Key stats such as the average daily volume over the past year has been around 808.01 thousand shares, trading with heavier-than-usual volume. Headquartered in Austin, TX, Genprex, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Ryan Confer, the company employs approximately 15 people and listed since March 29, 2018. Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes.

Genprex, Inc. trades at a P/E ratio of -0.1, slightly below the S&P 500 average, with a price-to-sales ratio of 380.97 and a price-to-book ratio of 2.29 suggesting the stock is closer to book value. The P/FCF stands at -0.25, also above market averages.

Our AI price prediction model suggests that Genprex, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -29.55%, with price expected at $1.55 by January 22, 2026, within a range of $1.17 to $1.94 3-Month Outlook: Projected fall of -74.09%, reaching $0.57 by April 08, 2026, with a range of $0.00 to $4.48. 1-Year Outlook: Projected loss of -91.82%, with price at $0.18 by December 31, 2026, within a range of $0.00 to $23.93.

Genprex, Inc. (NASDAQ:GNPX) shares are up 14.29% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Genprex, Inc. trading at a premium to the broader market with a P/E of -0.1. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $5.00, suggesting 127.27% upside. Our AI forecast model points to short-term weakness (-29.55% over two weeks), a medium-term fall (-74.09% over three months), and a longer-term loss (-91.82% over one year), with expected trading ranges indicating moderate volatility.